Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism

Lancet Oncol. 2010 Jun;11(6):507-509, Mary V Relling, Russ B Altman, Matthew P Goetz, William E Evans

After more than half a century of pharmacogenomic research, the clinical use of pharmacogenomic testing remains uncommon, despite many examples showing that inherited genomic variation causes substantial interindividual differences in drug effects. Since the sequences of pooled human genomes were made public,1,2 only a handful of pharmacogenetic tests have been translated into clinical laboratory tests. With the adoption of genetic non-discrimination laws,3 fewer legal arguments can be made for...

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

Editors' Choice

Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration